Huntsman (HUN): Buy the Merger Dip — Free Cash Flow Should Turn Positive as Scale Kicks In

Hook & thesis

Huntsman (HUN) is an industrial chemical franchiser that is trading like a distressed name, but the story is getting simpler: an all-stock merger with Olin announced in mid-June creates a larger, more diversified chemical platform with $12.5 billion of pro forma revenue and $300M+ of identifiable synergies targeted within two years. The market has punished Huntsman shares on deal economics and litigation headlines; that selloff, combined with a sub-1x price-to-book and modest leverage, offers a tactical entry for investors who believe management can execute on cost synergies and restore free cash flow.

My base case: scale from the Olin combination plus improving end markets for epoxy and coatings drive an earnings and free cash flow inflection through 2026-2027. If the synergies come through and working capital normalizes, Huntsman’s current market value - roughly $1.83 billion - understates the cash-generative potential of the combined business.

What Huntsman does and why the market should care

Huntsman manufactures differentiated organic chemical products across three segments: Polyurethanes, Performance Products, and Advanced Materials. Its Advanced Materials segment is exposed to epoxy and specialty resins used in coatings and composites; these markets benefit from longer-term trends toward low-VOC waterborne coatings and infrastructure spending. A market report cited a global waterborne epoxy resins opportunity growing toward an $8.5 billion market by 2034 - a structural tailwind for parts of Huntsman’s portfolio.

Why scale and synergies change the picture

The announced merger-of-equals with Olin (deal terms disclosed 06/16/2026) creates a larger player with $12.5 billion of combined revenue and management-identified benefits of more than $400 million, including over $300 million in synergies within 24 months. Scale matters in commodity and specialty chemicals: it improves purchasing leverage for feedstocks, allows rationalization of lower-return assets, and provides capacity to invest in higher-margin specialty lines. For a company currently valued at roughly $1.83 billion, the present value of those synergy gains - if realized - materially changes free cash flow forecasts.

Key financial and market anchors (selected numbers)

Two points to highlight from the table: first, valuation multiples are low across the board (P/B ~0.66, P/S ~0.30), signaling the market is pricing a weak recovery or structural damage. Second, the company has modest liquidity - roughly $200M in cash - and leverage under 1.0x on a debt-to-equity basis, which provides flexibility to manage integration costs and maintain dividends while synergies are executed.

Support for a free cash flow inflection

• Identified synergy pool of $300M+ within 24 months after the Olin merger - if even a portion is captured, earnings before interest and tax should rise materially.
• Structural demand growth in epoxy and waterborne resins (long-term CAGR cited ~6%) improves pricing power in select product lines.
• Modest leverage and $200M in cash give the combined company time to execute operational fixes without immediate refinancing pressure.
• Dividend continuity: the board declared a $0.0875 quarterly dividend (paid 06/30/2026), which provides an income floor for patient investors during the integration window.

Valuation framing

At a market cap of approximately $1.83 billion and enterprise value around $3.52 billion, Huntsman is priced like a company with limited earnings power. Price-to-book near 0.66 and price-to-sales roughly 0.3 are consistent with deep value territory for industrials. The critical adjustment here is the expected benefit from the merger and the speed of FCF recovery: if the combined company can deliver even half of the $300M synergy target, the incremental EBITDA could justify a meaningful re-rating versus current multiples.

Put simply: the valuation implies little or no benefit from the merger. That is a conservative starting point. The trade is a bet that the market will gradually price in some of the synergy upside and working capital normalization, which will push free cash flow positive and compress the EV/EBITDA multiple toward industry norms.

Catalysts (timeline sensitive)

• Integration updates and synergy realization milestones from management over the next 6-12 months - any concrete progress will remove uncertainty and re-rate the stock.
• Regulatory / shareholder litigation resolution or progress - removing deal closure risk will be a near-term de-risking event.
• Sector tailwinds: improvement in epoxy/resins demand or better feedstock pricing will materially boost margins.
• Quarterly reports showing working capital normalization and a move from negative to positive free cash flow.
• Market re-rating as industrials rotate back into cyclical chemicals on macro stability or improving manufacturing data.

Trade plan - actionable entry, stop, targets and horizon

My recommended trade is a long position with the following parameters:

• Entry: Buy at $10.30
• Stop loss: $8.50
• Target: $14.00
• Trade horizon: long term (180 trading days) - I expect the meaningful de-risking and synergy proof points to unfold over multiple quarters; however, I will monitor mid-term catalysts closely.

To be explicit on horizon language: short term (10 trading days) is how I would treat intraday noise and earnings reactions; mid term (45 trading days) is where I would expect initial integration commentary or regulatory updates; long term (180 trading days) is my preferred hold period for this trade because synergy capture and a free cash flow inflection typically take several quarters to materialize.

Position sizing and risk management

This is a medium-risk trade idea. Use disciplined position sizing so that a stop-out at $8.50 represents a loss you can tolerate. Reassess size if management reports material deal progress (outperformance) or if litigation materially increases the probability the transaction fails (downside risk greater).

Risks and counterarguments

• Deal execution and fairness concerns: Multiple shareholder law firms are investigating deal-related fairness (reports surfaced in June and July 2026), and litigation or regulatory pushback could delay or materially alter the economics of the transaction. If the merger is modified or fails, the post-announcement pricing already embeds concern; a deal collapse would likely pressure the stock below recent levels.
• Synergy realization uncertainty: Identified synergies are encouraging, but capture rates in mergers can be slow. If realized synergies fall well short of the $300M target, the valuation re-rating thesis weakens.
• Cyclical input-cost pressure: Huntsman is exposed to feedstock cost swings (e.g., oil, natural gas derivatives). A spike in input prices without corresponding price pass-through would compress margins and delay FCF recovery.
• Negative recent free cash flow: The most recent free cash flow figure is negative (-$9.0M). While the cash balance provides some buffer, continuing negative FCF without credible improvement would undercut the thesis.
• Short interest and volatility: There is a history of elevated short interest and intraday short-volume spikes. That creates two-way volatility: it can accelerate moves both up and down depending on news flow.

Counterargument: The most persuasive short case is that the market is correctly pricing in execution risk and potential value transfer to Olin shareholders under the deal terms. If the combined company structurally underperforms or management fails to capture synergies, the stock could languish or decline further. That is a realistic outcome and is the principal reason I advocate a disciplined stop and position sizing.

What would change my mind

I would become materially more bullish if we received early, verifiable synergy reports showing at least 30-50% of the identified cost savings realized within the first 12 months post-close, coupled with a clear move to positive free cash flow. Conversely, I would be quick to exit if the company discloses major integration hurdles, a highly dilutive financing need, or if litigation materially alters the deal consideration.

Conclusion

Huntsman is a classic event-driven value trade: low multiples, modest leverage, and a large, specific upside lever (merger synergies and scale) offset by real execution and legal risks. For patient, risk-aware investors, buying at $10.30 with a stop at $8.50 and a target of $14.00 over a 180 trading-day window offers an attractive asymmetric payoff if integration proceeds and end markets cooperate. Keep position size controlled, track synergy updates closely, and treat near-term headlines as noise unless they change the deal’s economics.

Recent relevant dates

• Merger announcement coverage: 06/16/2026
• Dividend declared (quarterly): 04/30/2026; payable 06/30/2026
• Law firm investigations surfaced: 06/19/2026, 06/24/2026, 07/10/2026, 08/04/2026